Biomedical

Pennsylvania State University dedicated the $144 million Chemical and Biomedical Engineering Building in April of 2019 in University Park. Designed by HOK, the six-story, 194,100-sf (109,100-asf) facility houses classrooms, conference rooms, collaboration spaces, instrumentation suites, a student commons, a 150-seat auditorium, and open labs arranged in neighborhoods to promote interaction. Transparent glass walls in interior corridors put science on display and integrated magnetic whiteboards encourage students and faculty to share ideas.

ONE Life Sciences is planning to construct the £40 million Bio-Therapeutics Hub for Innovation in Aberdeen in the United Kingdom. Located on the Foresterhill Health Campus, the 69,000-sf facility will provide business incubation space, leasable labs and offices for established companies, collaboration areas, conference rooms, and venues for events and colloquia.

The University of Toronto is planning to create Canada's largest university-based innovation node with the construction of the 750,000-sf Schwartz Reisman Innovation Centre. Funded in part by a $100 million donation, the interdisciplinary center will feature vertical gardens, soaring atria, and integrated collaboration areas, as well as offering leasable space for startup companies.

Virginia Commonwealth University opened the $87 million College of Health Professions in March of 2019 in Richmond. Designed by EYP Architecture and Engineering, the eight-story, 154,000-gsf facility unites nine departments in a sustainably designed structure that is expected to attain LEED Silver certification.

Bluebird Bio opened a 125,000-sf gene and cell therapy manufacturing facility in March of 2019 in Durham, N.C. Representing an $80 million investment, the project is bluebird's first wholly owned facility and will support the production of lentiviral vector for clinical and commercial applications. The building, which is now substantially complete and undergoing equipment commissioning, provides multiple manufacturing suites, quality-control testing labs, and warehouse space.

Inova Health System will open the 342,000-sf Schar Cancer Institute in May of 2019 in Fairfax, Va. Designed by Wilmot Sanz to provide comprehensive cancer care services in a single location, the patient-centric facility offers 124 exam rooms, 54 infusion chairs, diagnostic suites, advanced radiation therapy modalities, and a genetic counseling clinic.

Stanford University opened the $107 million Anne T. and Robert M. Bass Biology Research Building in March of 2019 in Palo Alto, Calif. Designed by Flad Architects and Ennead Architects to promote collaboration and interaction, the 133,000-sf facility provides wet biochemistry labs, dry computational labs, hybrid wet/dry research areas, and classrooms and offices for the Department of Biology.

Merck opened the first M Lab™ Collaboration Center in Europe in March of 2019. Located in Molsheim, France, the facility provides biopharmaceutical customers with a shared, exploratory environment where they can work with Merck scientists and engineers to accelerate the manufacture of new therapies. The 43,000-sf facility offers advanced simulation technologies in a non-GMP environment for end-to-end process development from pre-clinical through full-scale production.

Eisai is building the $100 million Center for Genetics Guided Dementia Discovery (G2D2) in Cambridge, Mass. Sited in the newly constructed Alewife Research Center, the 50,000-sf neuroscience facility will support exploratory drug research on next-generation dementia therapeutics. Featuring numerous interaction zones and huddle areas, the center will provide open offices, a collaboration hub, flexible meeting rooms, and multidisciplinary open labs for the study of biology, chemistry, and automation.

Vermeulens has released its market outlook report for the fourth quarter of 2018. Key points include:

Arizona State University and Wexford Science+Technology broke ground in March of 2019 on a $77 million research building on the Phoenix Biomedical Campus. The public-private project will be owned by Wexford and is being created in partnership with Ventas and the city of Phoenix. Half of the seven-story, 225,000-sf facility will house research labs for ASU's Biodesign Institute, the College of Health Solutions, and the College of Nursing and Health Innovation.

Cellectis entered into a lease agreement in March of 2019 to build the Innovative Manufacturing Plant for Allogeneic Cellular Therapies (IMPACT) in Raleigh, N.C. Designed by Laporte Euro, the facility will produce immunotherapies based on gene-edited allogeneic CAR T-cells (UCART). Colliers International assisted in the real estate transaction. In addition, Cellectis is building a 14,000-sf manufacturing facility in Paris.

Quest Diagnostics broke ground in March of 2019 on a 250,000-sf laboratory in Clifton, N.J. The medical testing facility will be Quest's largest development and will accommodate over 1,100 employees. Supporting increased capacity, the center will provide comprehensive diagnostic services with reduced processing times. Occupancy is expected in 2021. The lab is located on 12 acres in the ON3 campus which offers integrated research, office, and residential facilities in a vibrant environment offering myriad lifestyle amenities.

Lehigh University is planning to build a $100 million facility for the College of Health in Bethlehem, Pa. Designed by Wilson HGA, the five-story, 190,000-gsf facility will promote interdisciplinary education and research by collocating programs in health, science, and technology. Featuring a transparent design with minimal hard walls, the project will offer open labs and learning studios to enhance collaboration and interaction.

Amicus Therapeutics is creating the Global Research and Gene Therapy Center of Excellence in Philadelphia. The 75,000-sf facility will provide collaborative laboratories and offices for the discovery and development of treatments for rare metabolic diseases. Accommodating up to 200 employees, the center will serve as the headquarters for the global Amicus science organization and the gene therapy division’s leadership team. Occupancy is expected in the second half of 2019.